Opioids Market (Characteristics, Compounds,
Analgesics, Abuse) to 2018
Leading business intelligence provider GBI Research has released its latest research report, entitled
“Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter
Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad
and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of
underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most
patient populations experiencing more severe levels of pain across most pain indications, with the
exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class,
opioids have virtually no competition from molecules with non-opioid receptor targets. However,
although the competition is virtually exclusively limited to opioid compounds, the current environment
within this therapeutic class is highly competitive and strongly diversified. The approved drugs are based
on 16 different opioid compounds and are differentiated on a range of characteristics, which include
dosage, route of administration and pharmacokinetic features, as well as increasingly on the basis of
Request a Sample of this report @
Published: January 2013
No. of Pages: 43
Price: Single User License: US$3500 Corporate User License: US$10500
Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over
the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in
opioid abuse and dependency. Over the last few years, the growing concern over opioid abuse has
resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from
regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift
towards developing abuse-resistant formulations of extended-release opioid analgesics, including both
novel products and reformulations of existing ones. Since the launch of the first abuse-resistant product,
Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have
been brought to the opioid market. While abuse-resistant formulations do not confer any clinical
benefits, they have become an essential differentiating factor in the current market environment in
order ensure that products remain competitive for the future. There is a growing concentration and
competition among abuse-resistant products, which is expected to be the primary driving factor in this
largely stagnant market, particularly as the current developmental pipeline is very small and is
characterized by a lack of innovation, with virtually no novel compounds and strong saturation across
multiple pain indications.
An overview of the current opioid product market.
A brief discussion about the inconsistent prescription preferences among European physicians.
A brief profile of the most important opioid products.
A pipeline analysis of the opioid products currently in development and an overview of the
developmental pipeline by phase, by the route of administration and a summary of the
promising pipeline products.
An overview of the M&A and licensing deals, as well as co-development deals, across multiple
indications in which opioids are frequently used in patients suffering from moderate to severe
Reasons to buy
Identify trends in the developmental pipeline for opioid analgesics.
Develop their awareness of the regulatory environment, physician concerns and inconsistency
of prescription preferences among physicians.
Buy a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=213860.
Contact email@example.com for further information.